Can Fite Biopharma

Can Fite Biopharma Gross Margin

The Gross Margin of Can Fite Biopharma (CANF.TA) as of Oct 18, 2026 is 94.07 %. In the previous year, Gross Margin was 100.00 % — a change of -5.93% (lower).

Gross Margin

94.07 %

YoY

-5.93%

Last updated:

Gross Margin of Can Fite Biopharma is 2025 94.07 % . Gross Margin of Can Fite Biopharma was 2024 100.00 % . It decreases by -5.93% lower compared to the previous year.

Can Fite Biopharma's gross margin stands at 94.1%, down from 100.0% several years earlier.

The Can Fite Biopharma Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
100.00 USD
Jan 1, 2019
100.00 USD
Jan 1, 2020
100.00 USD
Jan 1, 2021
100.00 USD
Jan 1, 2022
100.00 USD
Jan 1, 2023
100.00 USD
Jan 1, 2024
100.00 USD
Jan 1, 2025
94.07 USD
The Can Fite Biopharma Gross Margin history
YEARGross MarginYoY
94.07 %-5.93%
100.00 %0.00%
100.00 %0.00%
100.00 %0.00%
100.00 %0.00%
100.00 %0.00%
100.00 %0.00%
100.00 %0.00%
100.00 %0.00%
100.00 %0.00%
100.00 %+9,900.00%
1.00 %0.00%
1.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Can Fite Biopharma Stock analysis

What does Can Fite Biopharma do? Can-Fite Biopharma Ltd. is an Israeli company specializing in the development of drugs for inflammatory diseases and cancer. It was founded in 1994 by Prof. Pnina Fishman and is headquartered in Petach Tikva, Israel. The company initially focused on studying the function of adenosine receptors in central nervous system diseases, but later expanded to develop drugs for inflammatory diseases and cancer. Can-Fite went public in 2007 and has been able to finance its research projects through investors and partnerships. The company's business model revolves around developing an innovative portfolio of drugs for immune system disorders and cancer by targeting adenosine receptors. It aims to expand its drug pipeline to successfully treat a wide range of diseases. Can-Fite's drug pipeline is divided into different areas, including inflammatory diseases, cancer, and ophthalmology. The company has already brought several drugs to market or is in the clinical testing phase, including CF101 for rheumatoid arthritis and psoriasis, Namodenoson for liver cancer, and Piclidenoson for autoimmune diseases. Overall, Can-Fite Biopharma Ltd. is a promising company focused on developing innovative drugs for inflammatory diseases and cancer. Can Fite Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Can Fite Biopharma stock

Gross Margin of Can Fite Biopharma is 94.07 % in 2025.

Gross Margin of Can Fite Biopharma changed from 100.00 % to 94.07 %, representing a -5.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Can Fite Biopharma since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Can Fite Biopharma with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Can Fite Biopharma

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Can Fite Biopharma